Competition and Markets Authority to probe ABF’s deal to buy Hovis

Associated British Foods agreed in August to buy 135-year-old Hovis from US private equity owner Endless and plans to merge it with its Allied Bakeries unit (maker of Kingsmill and Allinson’s) to capture scale and cost synergies. The UK Competition and Markets Authority has opened a formal phase-one probe following earlier requests for feedback and will decide by Feb. 19 whether a more detailed phase-two investigation is required, introducing regulatory risk to the transaction. ABF says the deal addresses Allied Bakeries’ recent losses by creating a more sustainable, investable competitor amid changing consumer demand and cost pressures.

Analysis

Market structure: Approval would create a consolidated UK branded-bread leader (ABF.L + Hovis) with scale to squeeze retailer own-label promotions and reduce per-unit logistics costs; expect mid-single-digit EBITDA margin uplift (3–5%) across combined Allied/Hovis within 12–24 months if fully integrated, with Warburtons and supermarket private labels as direct competitive losers in branded shelf space and pricing power.

Risk assessment: The principal tail risk is a CMA Phase‑2 referral or divestment remedy (we estimate mid-20s% probability given sector sensitivity) that would materially reduce synergies and could drive a 8–15% one-off share re-rating; short-term event risk clusters around the regulator’s February 19 deadline (per article) and market reaction windows (±48 hours of any referral) while long-term execution risk is integration loss of sales over 12–18 months.

Trade implications: Event-driven trades should be sized small and hedged — ABF implied vol will reprice into any referral; expect 3–8% intraday moves on news. Cross-asset: modest tightening in ABF credit spreads if approved, small upward pressure on UK wheat hedges by large buyer, and transient GBP defensive bid into staples on deal clarity. Use directional and relative-value positions with option collars/put-spreads to cap downside ahead of regulatory milestones.

Contrarian angles: Consensus fixates on regulatory blocking risk but under-appreciates Allied’s prior losses — transaction could be defensive value-creation rather than aggressive market-share grab; historical CMA-approved remedies in UK grocery have caused only temporary share weakness before recovery (6–12 months). An adverse remedy could create stand-alone bakery assets attractive to PE — a secondary M&A/arbitrage opportunity to monitor.

Key Decisions for Investors

• Establish a 2–3% long position in Associated British Foods (LSE: ABF.L) with a 12-month horizon to capture 3–5% expected EBITDA uplift if approved; immediately hedge with a 3-month 10% OTM put sized to limit downside to ~0.5% portfolio risk; trim the long within 48 hours if CMA refers the deal to Phase‑2 or if ABF falls more than 8% on the news.
• Buy an event put-spread on ABF.L to protect and monetize implied vol: purchase a 3-month 8% OTM put and sell a 15% OTM put (ratio sized to cost <0.2% portfolio); close position on regulatory approval or at expiry—this caps downside while keeping long exposure to integration upside.
• Run a relative-value pair trade: long ABF.L (2%) vs short Sainsbury (LSE: SBRY.L) or Tesco (LSE: TSCO.L) (1.5%) for 6–12 months to capture branded-share recovery; unwind the short if supermarket gross margins expand >100bps on the next quarter or if ABF is referred to Phase‑2, and trim long if ABF rallies >12% pre-approval.
• If CMA refers to Phase‑2 and ABF sells off >10%, opportunistically add to ABF to a 4% position (add-on) with a hard stop at -15% from entry; rationale is discounted entry into a structurally consolidated asset where divestiture remedies could create separable, value-accretive businesses over 12–24 months.